4.4 Article

HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years

Journal

AIDS
Volume 24, Issue 5, Pages 763-771

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e3283366747

Keywords

epidemiology; HIV/AIDS; immigration; industrialized country; tuberculosis

Funding

  1. Institut National de la Sante et de la Recherche Medicale (INSERM)
  2. Agence Nationale de la Recherche sur le SIDA (ANRS)
  3. French Ministry of Health

Ask authors/readers for more resources

Objective: To examine trends in tuberculosis incidence rates in France during the combination antiretroviral therapy (cART) period. Methods: From the French Hospital Database on HIV, we selected 72 580 patients (including 14 491 migrants) with no history of tuberculosis, followed between 1 January 1997 and 31 December 2008. We then examined incidence rates of tuberculosis and its risk factors. Results: A total of 2625 patients were diagnosed with tuberculosis either at enrolment (N = 932) or during follow-up (N = 1693). During follow-up, the incidence rate of tuberculosis was 0.40/100 patient-years overall, 0.20 among nonmigrants and 1.03 among migrants. Adjusted risk of tuberculosis was 2.01 [95% confidence interval (CI) 1.79-2.26] times higher in migrants than in nonmigrants. The adjusted incidence rate of tuberculosis significantly increased in both migrants and nonmigrants after 2000-2001, with adjusted risks of 2.50 (95% CI 1.54-4.06) and 1.85 (95% CI 1.27-2.69) in 2008 compared with that in 1997, respectively. Other factors independently associated with a higher incidence of tuberculosis were medical follow-up less than or equal to 6 months, no previous antiretroviral therapy, lower CD4 cell count and higher viral load. Nonmigrant patients belonging to HIV-transmission groups other than homosexual men, residing in the Paris area or in French West Indies or with AIDS status were at a supplementary risk. Conclusion: The incidence of tuberculosis is increasing among both migrant and nonmigrant HIV-infected patients in France. This is partly because sub-Saharan African migrants represent an increasing fraction of the HIV-infected population in France and also because of late access to care. Co-prescribing tuberculosis preventive therapy with cART might benefit selected patients, such as migrants and patients with late access to care. (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Maud Lemoine, Lambert Assoumou, Pierre-Marie Girard, Marc Antoine Valantin, Christine Katlama, Stephane De Wit, Pauline Campa, Hayette Rougier, Jean-Luc Meynard, Coca Necsoi, Anja D. Huefner, Jan Van Luzen, Julian Schulze Zur Wiesch, Jean-Philippe Bastard, Soraya Fellahi, Stefan Mauss, Metodi V. Stankov, Axel Baumgarten, Gerrit Post, Lawrence Serfaty, Vlad Ratziu, Yves Menu, Jerome Schlue, Pierre Bedossa, Jacqueline Capeau, Dominique Costagliola, Georg Behrens, Patrick Ingiliz

Summary: This study aimed to assess the prevalence and associated factors of liver steatosis and advanced fibrosis (AF) in HIV-monoinfected patients at risk of NAFLD. The results showed that two-thirds of the HIV-monoinfected patients with NAFLD had liver steatosis, and around 10% had advanced fibrosis. The CAP technique was accurate for screening steatosis in this population.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Immunology

Prevalence and risk factors of frailty among adults living with HIV aged 70years or older

Clotilde Allavena, Hubert Blain, Xian Abulizi, Laurence Slama, Christine Katlama, Pierre Delobel, Vanessa Rio, Carole Cagnot, Mariem Raho-Moussa, Alain Makinson, Laurence Meyer

Summary: This study aimed to assess the prevalence and risk factors of frailty in people aged 70 years or older with HIV who were on antiretroviral treatment. The results showed a low prevalence of frailty (13.5%) and a high prevalence of prefrailty (63.3%) in this population. Age, low socioeconomic status, and multimorbidities were associated with frailty. These findings highlight the importance of targeting these factors to promote successful aging in older individuals with HIV.
Article Immunology

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

Laura Waters, Lambert Assoumou, Ana Gonzalez-Cordon, Stefano Rusconi, Pere Domingo, Mark Gompels, Stephane de Wit, Francois Raffi, Christoph Stephan, Mar Masia, Jurgen Rockstroh, Christine Katlama, Georg M. N. Behrens, Graeme Moyle, Margaret Johnson, Julie Fox, Hans-Jurgen Stellbrink, Giovanni Guaraldi, Eric Florence, Stefan Esser, Jose M. Gatell, Anton Pozniak, Esteban Martinez

Summary: In the NEAT022 trial, virologically suppressed HIV patients at high cardiovascular risk switching from protease inhibitors to dolutegravir showed noninferior virological suppression and significant reductions in lipid and cardiovascular disease risk, regardless of immediate or delayed switching.

CLINICAL INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohort

Jade Ghosn, Delphine Bachelet, Marine Livrozet, Minerva Cervantes-Gonzalez, Julien Poissy, Francois Goehringer, Charlotte Salmon Gandonniere, Mylene Maillet, Firouze Bani-Sadr, Guillaume Martin-Blondel, Pierre Tattevin, Odile Launay, Laure Surgers, Emmanuel Dudoignon, Geoffroy Liegeon, David Zucman, Cedric Joseph, Eric Senneville, Cecile Yelnik, Pierre-Marie Roger, Karine Faure, Marie Gousseff, Andre Cabie, Xavier Duval, Catherine Chirouze, Cedric Laouenan

Summary: This study assessed the symptoms that persisted 12 months after admission for COVID-19 and found that approximately 27% of patients still had >= 3 persistent symptoms, especially fatigue, dyspnea, and joint pain. Women were more likely to experience persistent symptoms, as well as suffer from anxiety and depression, and were less likely to return to work compared to men.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Article Immunology

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

Romain Palich, Rachid Agher, Dimoke J. Wetshikoy, Lise Cuzin, Sophie Seang, Cathia Soulie, Roland Tubiana, Marc-Antoine Valantin, Luminita Schneider, Valerie Pourcher, Anne-Genevieve Marcelin, Lambert Assoumou, Christine Katlama

Summary: This study aims to explore the differences in antiretroviral therapy (ART) prescriptions between naive and virally suppressed HIV patients born in France and Sub-Saharan Africa. The findings suggest that the differences in ART prescriptions between these two groups cannot solely be explained by different clinical and virologic situations.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2023)

Article Public, Environmental & Occupational Health

Impact of Smoking on Functional Prognosis after Ischemic Stroke according to Deprivation: A Prospective Cohort Study

Emmanuel Delmas, Abderrahmane Bourredjem, Mathieu Nacher, Andre Cabie, Emmanuelle Mimeau, Claire Bonithon-Kopp, Devi Rochemont, Marie-Laure Lalanne-Mistrih, Caroline Misslin-Tritsch, Julien Joux, Annie Lannuzel, Isabelle Fournel, Yannick Bejot

Summary: This study aimed to assess the joint impact of deprivation and smoking on functional outcomes after ischemic stroke. The study found that smokers had a higher likelihood of moderate to severe disability at 12 months compared to nonsmokers in nondeprived patients. However, there was no significant association between smoking and disability in deprived patients.

NEUROEPIDEMIOLOGY (2023)

Article Chemistry, Medicinal

Chemical scaffold recycling: Structure-guided conversion of an HIV integrase inhibitor into a potent influenza virus RNA-dependent RNA polymerase inhibitor designed to minimize resistance potential

Peter J. Slavish, Maxime G. Cuypers, Mary Ashley Rimmer, Alireza Abdolvahabi, Trushar Jeevan, Gyanendra Kumar, Jamie A. Jarusiewicz, Sivaraja Vaithiyalingam, Jeremy C. Jones, John J. Bowling, Jeanine E. Price, Rebecca M. DuBois, Jaeki Min, Richard J. Webby, Zoran Rankovic, Stephen W. White

Summary: Influenza is a major cause of disease-related deaths globally. Strategies to inhibit influenza virus replication have resulted in the emergence of resistant strains. Baloxavir marboxil, a recently approved compound, is significantly less effective due to a mutation in the active site of the target enzyme. Raltegravir, an HIV inhibitor, shows moderate activity against the enzyme. In this study, researchers used structure-guided approaches to design molecules that effectively target the enzyme's active site and successfully developed potent inhibitors for both wild-type and baloxavir-resistant forms.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Infectious Diseases

Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis

Laurent Hocqueloux, Amelie Menard, Cedric Arvieux, Veronique Joly, Agathe Becker, Antoine Cheret, Claudine Duvivier, Andre Cabie, Cyrille Delpierre, Clotilde Allavena

Summary: This study aimed to describe the changes in weight and BMI following the substitution of TDF by TAF in PLWH. The results showed that there was a significant weight gain and increase in BMI in the Switch group, which should be taken into consideration in at-risk populations.

HIV MEDICINE (2023)

Article Infectious Diseases

Low-level viral loads and virological failure in the integrase strand transfer era

Lise Cuzin, Philippe Flandre, Clotilde Allavena, Romain Palich, Claudine Duvivier, Agathe Becker, Helene Laroche, Pascal Pugliese, Andre Cabie, Dat'AIDS Study Grp

Summary: This study analyzed the occurrence of virological failure (VF) in patients starting ART with an integrase strand transfer inhibitor (INSTI)-based regimen in recent years and its relationship with previous episodes of low-level viral load (LLVL). The results showed that LLVL was associated with VF, and even in the absence of subsequent failure, LLV episodes have a cost. Therefore, any viral load value above 50 copies/mL should lead to enhanced adherence counseling.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Virology

Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children

Djeneba B. Fofana, Houdou Diarra, Ibrahima Guindo, Mahamadou K. Savadogo, Marceline d'Almeida, Fatoumata I. Diallo, Aliou Balde, Cathia Soulie, Amadou Kone, Anne-Genevieve Marcelin, Almoustapha I. Maiga, Sidonie Lambert-Niclot, Mamoudou Maiga, Sally McFall, Claudia A. Hawkins, Robert L. Murphy, Mariam Sylla, Christine Katlama, Jane L. Holl, Vincent Calvez, Laurence Morand-Joubert

Summary: Limited data exist on INI resistance in children living with HIV/AIDS in West Africa. A study was conducted on HIV-1-infected children in Benin and Mali, and it was found that no major INI resistance mutations were detected in INI-naive patients.

VIRUSES-BASEL (2023)

Article Critical Care Medicine

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola

Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.

CRITICAL CARE (2023)

Review Critical Care Medicine

Effects of remdesivir in patients hospitalised with COVID-19 a systematic review and individual patient data meta- analysis of randomised controlled trials

Alain Amstutz, Benjamin Speich, France Mentre, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Charles Burdet, Srinivas Murthy, Lori Elizabeth Dodd, Yeming Wang, Kari A. O. Tikkinen, Florence Ader, Maya Hites, Maude Bouscambert, Mary Anne Trabaud, Mike Fralick, Todd C. Lee, Ruxandra Pinto, Andreas Barratt-Due, Fridtjof Lund-Johansen, Fredrik Mueller, Olli P. O. Nevalainen, Bin Cao, Tyler Bonnett, Alexandra Griessbach, Ala Taji Heravi, Christof Schonenberger, Perrine Janiaud, Laura Werlen, Soheila Aghlmandi, Stefan Schandelmaier, Yazdan Yazdanpanah, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel

Summary: This systematic review and meta-analysis assessed the benefits and harms of remdesivir compared to placebo or usual care in COVID-19 patients hospitalized. The study found that remdesivir reduced mortality in patients who required no or conventional oxygen support but did not have enough evidence for patients on ventilators.

LANCET RESPIRATORY MEDICINE (2023)

Article Infectious Diseases

Knowledge on human papillomavirus (HPV), HPV screening and HPV vaccine among sexual health clinic patients in Martinique, French West Indies

O. Cabras, L. Sylvanise, A. Marquise, A. Cabie, L. Cuzin

Summary: This study aimed to assess the level of knowledge about HPV among a population attending a sexual health clinic in the University Hospital of Martinique. A validated questionnaire was used to survey 500 young adults, and the results indicated that 68% of participants had never heard of HPV, with the percentage rising to 74.6% among women. The median number of correct answers out of 28 questions was 15, and there was no significant difference related to age. Women had more correct answers on most of the items related to screening and vaccine. The study highlights the poor knowledge about HPV in Martinique and the need for new communication methods to reach young boys and girls.

INFECTIOUS DISEASES NOW (2023)

No Data Available